Clinical Research Directory
Browse clinical research sites, groups, and studies.
Assessment of Geriatric Evaluations Impact on New AML Guidance
Sponsor: Abramson Cancer Center at Penn Medicine
Summary
The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.
Official title: AGE-ING (Assessment of Geriatric Evaluations Impact on New AML Guidance) Study
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2023-10-25
Completion Date
2026-12-01
Last Updated
2025-08-07
Healthy Volunteers
No
Conditions
Locations (1)
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States